Johnson & Johnson's ($JNJ) new Prezista formulation, a once-daily 800 mg pill, won approval from European regulators. The FDA gave its blessing to the new HIV drug in November. The original Prezista is set to lose exclusivity in 2017. Report
The MedTech industry has hit an inflection point and opportunities abound for companies to deliver broader solutions that healthcare providers are looking for. L.E.K. Consulting presents a hospital segmentation framework that illustrates four dimensions of changes affecting providers and defines six main areas of strategic focus to drive success for MedTechs. Download White Paper Today.
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!